---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012295"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:00:46.034893+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# uniQure doses first patient in Phase I/IIa AMT-191 Fabry disease trial

## Summary
- First patient dosed in open-label, two-cohort Phase I/IIa trial of AMT-191 gene therapy for Fabry disease.
- Low-dose cohort: 6e10^13 gc/kg; high-dose: 3e10^14 gc/kg; one-time IV infusion; 24-month follow-up.
- AMT-191 uses same AAV5 delivery as HEMGENIX; targets liver to produce GLA protein.
- CEO cites catalysts: FDA engagement for AMT-130 (Huntington's), new trials in epilepsy and SOD1-ALS.
- Cash runway extended through end of 2027 from cost reduction initiatives.

## SEC filing metadata
- accession: 0001558370-24-012295
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837024012295/0001558370-24-012295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837024012295/qure-20240815x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012295
- JSON: https://secwatch.observer/filing/0001558370-24-012295.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.